179 related articles for article (PubMed ID: 22846229)
1. Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-α antagonists via the suppression of TNF-α expression and NF-κB pathway in rats.
Wang Q; Zuo XR; Wang YY; Xie WP; Wang H; Zhang M
Vascul Pharmacol; 2013 Jan; 58(1-2):71-7. PubMed ID: 22846229
[TBL] [Abstract][Full Text] [Related]
2. Ruscogenin attenuates monocrotaline-induced pulmonary hypertension in rats.
Bi LQ; Zhu R; Kong H; Wu SL; Li N; Zuo XR; Zhou SM; Kou JP; Yu BY; Wang H; Xie WP
Int Immunopharmacol; 2013 May; 16(1):7-16. PubMed ID: 23538027
[TBL] [Abstract][Full Text] [Related]
3. Betaine Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats via Inhibiting Inflammatory Response.
Yang JM; Zhou R; Zhang M; Tan HR; Yu JQ
Molecules; 2018 May; 23(6):. PubMed ID: 29861433
[TBL] [Abstract][Full Text] [Related]
4. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats.
Shi R; Wei Z; Zhu D; Fu N; Wang C; Yin S; Liang Y; Xing J; Wang X; Wang Y
Pulm Pharmacol Ther; 2018 Feb; 48():124-135. PubMed ID: 29133079
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol inhibits monocrotaline-induced pulmonary arterial remodeling by suppression of SphK1-mediated NF-κB activation.
Shi W; Zhai C; Feng W; Wang J; Zhu Y; Li S; Wang Q; Zhang Q; Yan X; Chai L; Liu P; Chen Y; Li M
Life Sci; 2018 Oct; 210():140-149. PubMed ID: 30179628
[TBL] [Abstract][Full Text] [Related]
6. Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering.
Mawatari E; Hongo M; Sakai A; Terasawa F; Takahashi M; Yazaki Y; Kinoshita O; Ikeda U
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):594-600. PubMed ID: 17581214
[TBL] [Abstract][Full Text] [Related]
7. Preventive and remedial application of etanercept attenuate monocrotaline-induced pulmonary arterial hypertension.
Zhang LL; Lu J; Li MT; Wang Q; Zeng XF
Int J Rheum Dis; 2016 Feb; 19(2):192-8. PubMed ID: 24612527
[TBL] [Abstract][Full Text] [Related]
8. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
9. Salusin-β contributes to vascular inflammation associated with pulmonary arterial hypertension in rats.
Xu T; Zhang Z; Liu T; Zhang W; Liu J; Wang W; Wang J
J Thorac Cardiovasc Surg; 2016 Oct; 152(4):1177-87. PubMed ID: 27353339
[TBL] [Abstract][Full Text] [Related]
10. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation.
Zhai C; Shi W; Feng W; Zhu Y; Wang J; Li S; Yan X; Wang Q; Zhang Q; Chai L; Li C; Liu P; Li M
Life Sci; 2018 Sep; 208():87-95. PubMed ID: 30009823
[TBL] [Abstract][Full Text] [Related]
11. 5-Aminosalicylic Acid Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats by Increasing the Expression of Nur77.
Sun LY; Cai ZY; Pu J; Li J; Shen JY; Yang CD; He B
Inflammation; 2017 Jun; 40(3):806-817. PubMed ID: 28213866
[TBL] [Abstract][Full Text] [Related]
12. Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats.
Lu J; Shimpo H; Shimamoto A; Chong AJ; Hampton CR; Spring DJ; Yada M; Takao M; Onoda K; Yada I; Pohlman TH; Verrier ED
J Thorac Cardiovasc Surg; 2004 Dec; 128(6):850-9. PubMed ID: 15573069
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension.
Kimura S; Egashira K; Chen L; Nakano K; Iwata E; Miyagawa M; Tsujimoto H; Hara K; Morishita R; Sueishi K; Tominaga R; Sunagawa K
Hypertension; 2009 May; 53(5):877-83. PubMed ID: 19307469
[TBL] [Abstract][Full Text] [Related]
14. Ruscogenin exerts beneficial effects on monocrotaline-induced pulmonary hypertension by inhibiting NF-κB expression.
Zhu R; Bi L; Kong H; Xie W; Hong Y; Wang H
Int J Clin Exp Pathol; 2015; 8(10):12169-76. PubMed ID: 26722401
[TBL] [Abstract][Full Text] [Related]
15. Effects of TNF-alpha blockade in monocrotaline-induced pulmonary hypertension.
Henriques-Coelho T; Brandão-Nogueira A; Moreira-Gonçalves D; Correia-Pinto J; Leite-Moreira AF
Rev Port Cardiol; 2008 Mar; 27(3):341-8. PubMed ID: 18551920
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of endocan attenuates monocrotaline-induced connective tissue disease related pulmonary arterial hypertension.
Zhao H; Xue Y; Guo Y; Sun Y; Liu D; Wang X
Int Immunopharmacol; 2017 Jan; 42():115-121. PubMed ID: 27912147
[TBL] [Abstract][Full Text] [Related]
17. Srolo Bzhtang reduces inflammation and vascular remodeling via suppression of the MAPK/NF-κB signaling pathway in rats with pulmonary arterial hypertension.
Chen T; Su S; Yang Z; Zhang D; Li Z; Lu D
J Ethnopharmacol; 2022 Oct; 297():115572. PubMed ID: 35872290
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of nuclear factor-κB in the lungs prevents monocrotaline-induced pulmonary hypertension in mice.
Li L; Wei C; Kim IK; Janssen-Heininger Y; Gupta S
Hypertension; 2014 Jun; 63(6):1260-9. PubMed ID: 24614212
[TBL] [Abstract][Full Text] [Related]
19. The protective effects of PCPA against monocrotaline-induced pulmonary arterial hypertension are mediated through the downregulation of NFAT-1 and NF-κB.
Bai Y; Li ZX; Wang HL; Lian GC; Wang Y
Int J Mol Med; 2017 Jul; 40(1):155-163. PubMed ID: 28560440
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor improves the survival of rats with pulmonary arterial hypertension via the amelioration of pulmonary hemodynamics.
Hiramine K; Sata N; Ido A; Kamimura R; Setoyama K; Arai K; Nuruki N; Tanaka Y; Uto H; Tsubouchi H
Int J Mol Med; 2011 Apr; 27(4):497-502. PubMed ID: 21318217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
